Stocks Health care ARCT
NASDAQ · Health careArcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. brought in $30.5M of revenue over the twelve months to September 30, 2026, down 68.7% from a year earlier. It posted a net loss of $87.2M. In fiscal 2025 capital spending exceeded operating cash flow by $74.5M. At September 30, 2026 it held $184.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Arcturus Therapeutics Holdings Inc.
- Net worth
- Arcturus Therapeutics Holdings Inc. has a market value (market cap) of $266.9M at the latest share price, and shareholders' equity of $168.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $82M (-46.1% year on year), with a net loss of $65.8M. Over the 12 months to September 30, 2026: revenue $30.5M, net loss $87.2M.
- Cash flow
- In fiscal 2025 operations used $74.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Arcturus Therapeutics Holdings Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Arcturus Therapeutics Holdings Inc. does
Arcturus Therapeutics Holdings Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARCT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $82M | -$65.8M | -$2.40 | -$74.5M |
| 2024 | $152.3M | -$80.9M | -$3.00 | -$60.4M |
| 2023 | $166.8M | -$29.7M | -$1.12 | -$21M |
| 2022 | $206M | $9.3M | $0.35 | $24.3M |
| 2021 | $12.4M | -$203.7M | -$7.74 | -$138.4M |
| 2020 | $9.5M | -$72.1M | -$3.55 | -$44.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ARCT ranks in Health care
Latest SEC filings
What Arcturus Therapeutics Holdings Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 6.7% to $18.3M versus the same quarter last year; diluted EPS -$0.26 versus -$0.49.
- November 5, 2026
- October 29, 2026Passive stake changed SCHEDULE 13G/A
- September 23, 2026
- August 25, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 90% to $3M versus the same quarter last year; diluted EPS -$0.84 versus -$0.34.
- August 6, 2026
- July 2, 2026
- June 5, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 93% to $2.1M versus the same quarter last year; diluted EPS -$0.95 versus -$0.52.
Insider trades
What the people running Arcturus Therapeutics Holdings Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns ARCT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ARK Investment Management LLC13G, passive with 1 related filers | 10.37% | May 7, 2026 |
| Amova Asset Management Americas, Inc.13G, passive | 7.2% | November 13, 2025 |
| Sumitomo Mitsui Trust Group, Inc.13G, passive with 1 related filers | 5.9% | October 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 135 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Federated Hermes, Inc. | 3,303,640 | 0 |
| ARK Investment Management LLC | 2,901,635 | +132,117 |
| BlackRock, Inc. | 2,614,012 | +731 |
| Sumitomo Mitsui Trust Group, Inc. | 1,963,123 | -325,812 |
| Amova Asset Management Americas, Inc. | 1,960,458 | -328,477 |
| Vanguard Capital Management LLC | 1,114,956 | +7,936 |
| Two Sigma Investments, LP | 1,091,137 | +9,353 |
| Vanguard Portfolio Management LLC | 951,575 | -26,347 |
| Geode Capital Management, LLC | 693,660 | +32,732 |
| Aqr Capital Management LLC | 675,014 | +513,736 |
| Jacobs Levy Equity Management, Inc | 647,511 | +448,783 |
| State Street Corp | 569,598 | +25,735 |
| UBS Group AG | 490,632 | +32,355 |
| D. E. Shaw & Co., Inc. | 392,358 | +140,324 |
| Empire Life Investments Inc. | 366,217 | -17,276 |
| Hennion & Walsh Asset Management, Inc. | 346,207 | +66,528 |
| Millennium Management LLC | 336,996 | -141,561 |
| Goldman Sachs Group Inc | 309,863 | +111,182 |
| Bnp Paribas Financial Markets | 261,789 | +66,929 |
| Charles Schwab Investment Management Inc | 231,628 | +15,128 |
Insiders
Questions about ARCT
What does Arcturus Therapeutics Holdings Inc. do?
Arcturus Therapeutics Holdings Inc. is a company in the Health care sector, listed on NASDAQ as ARCT. Its shares trade on NASDAQ under the ticker ARCT.
What is Arcturus Therapeutics Holdings Inc.'s net worth?
Arcturus Therapeutics Holdings Inc. has a market value (market cap) of $266.9M at the latest share price, and shareholders' equity of $168.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Arcturus Therapeutics Holdings Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $87.2M on revenue of $30.5M.
How much revenue does Arcturus Therapeutics Holdings Inc. make?
Over the twelve months to September 30, 2026 Arcturus Therapeutics Holdings Inc. reported revenue of $30.5M. That is 68.7% less than a year earlier.
When did Arcturus Therapeutics Holdings Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Arcturus Therapeutics Holdings Inc.'s next earnings report?
Arcturus Therapeutics Holdings Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ARCT with
Follow ARCT
Get an email when Arcturus Therapeutics Holdings Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Arcturus Therapeutics Holdings Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.